Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan

Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Toriyama K, Hijioka S, Komoto I, Kobayashi N, Okusaka T,

Keywords: prop-up, japan, gep-nen,

#1724 Outcomes of Hepatobiliary Neuroendocrine Neoplasms Treated with Systemic Therapy: A Retrospective Analysis.

Introduction: Primary hepatobiliary neuroendocrine neoplasms (NEN) are rare. Knowledge about clinicopathological findings and treatment results of hepatobiliary NEN is limited.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Satoshi K, Chigusa M, Takuji O, Yasunari S, Shunsuke K,

Keywords: primary, hepatobiliary, neuroendocrine, neoplasms,

#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System

Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Masui T

Authors: Masui T, Imamura M, Ito T, Unno M, Okusaka T,

Keywords: registry system, Japan,,

#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3

Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Okusaka T, Ito T, Ikeda M, Tajima T, Kasuga A,

Keywords: mTOR, everolimus, octreotide LAR, neuroendocrine tumor,